Grant Pharmacy
Hassle-Free Shopping
Live healthy
Care for your health needs
Affordable prescription drugs to all people
We respect our customer privacy
Reorder Coupons

Total Privacy

Privacy

Enjoy private and confidential shopping with complete peace of mind.

Total Security

Security

Your personal information is never shared. We follow strict security standards to keep your data safe and confidential.

Home / Allergy /   Bilafav M Odt (Bilastine 10 Mg+Montelukast 4 Mg)

Bilafav M Odt (Bilastine 10 Mg+Montelukast 4 Mg)

Bilafav M Odt (Bilastine 10 Mg+Montelukast 4 Mg)

Category:Allergy
Active substance:Bilastine 10 Mg+Montelukast 4 Mg
Prescription:Upload it in Checkout.
Manufacturer:Cipla Ltd
Customer rate:
Share
Save

Bilafav M Odt (Bilastine 10 Mg+Montelukast 4 Mg)

PackageOur PricePer PillActions
30 Tabs
$27.90
$0.93
60 Tabs
$51.60
$0.86
90 Tabs
$71.10
$0.79
120 Tabs
$86.40
$0.72
Air Mail
180 Tabs
$117.00
$0.65
Air Mail
270 Tabs
$156.60
$0.58
Air Mail
360 Tabs
$183.60
$0.51
Air Mail

Usage

Bilafav M Odt (Bilastine 10 Mg+Montelukast 4 Mg)

 

Introduction

Bilafav M Odt is an orodispersible combination medicine containing Bilastine 10 mg and Montelukast 4 mg. Bilastine is a second-generation antihistamine that blocks histamine activity, while montelukast is a leukotriene receptor antagonist that reduces the effects of inflammatory substances called leukotrienes.

 This combination is used for clinician-directed management of allergic conditions, particularly allergic rhinitis. Shop Bilafav M ODT 10/4 Tablet online from Grant Pharmacy, subject to prescription verification and availability.

The Bilafav M ODT 10/4 strength differs from standard adult bilastine and montelukast strengths. Bilastine 10 mg orodispersible formulations are used in paediatric treatment in regulated markets, while montelukast 4 mg is also a paediatric strength in established prescribing information.

 The suitability of this particular combination depends on the patient's age, body weight, diagnosis, medical history, and clinician's instructions. It should not be replaced with bilastine 20 mg or montelukast 10 mg without professional guidance.

 

Bilafav M ODT Tablet Uses

Bilafav M ODT tablet uses are mainly related to allergic conditions in which histamine and leukotrienes contribute to symptoms.

Allergic rhinitis can cause:

  • repeated sneezing
  • nasal itching
  • a runny nose
  • nasal blockage
  • itchy or watery eyes and
  • discomfort following exposure to allergens.

Common allergy triggers include pollen, house dust mites, mould, and animal allergens. When the immune system reacts to these triggers, several chemical mediators are released.

Bilastine targets histamine activity, while montelukast acts on leukotrienes. Combining these mechanisms can help manage different components of an allergic response when combination therapy is considered appropriate.

Bilafav M ODT controls symptoms rather than removing the underlying allergen. Reducing exposure to identified triggers can remain an important part of allergy management.

 

How Bilastine 10 mg Works

Bilastine is a selective peripheral H1 histamine-receptor antagonist.

Histamine is released during allergic reactions and attaches to H1 receptors in tissues. This contributes to sneezing, itching, nasal discharge, watery eyes, and other typical allergy symptoms.

The bilastine 10 mg component blocks these receptors and reduces histamine-related symptoms.

Bilastine is considered a second-generation antihistamine because it has limited penetration into the central nervous system compared with many older antihistamines. This generally gives it a lower tendency to cause sedation.

Bilastine 10 mg orodispersible tablets have been used as a paediatric formulation. Licensed bilastine information supports 10 mg once daily in certain children, with the appropriate age and minimum body-weight criteria depending on the specific regulatory product information. This paediatric dose provides exposure comparable with the standard bilastine 20 mg adult dose.

That information should not be used to calculate a dose independently. Bilafav M ODT is a combination product, and its dosing should follow the specific prescription.

 

How Montelukast 4 mg Works

Montelukast belongs to the leukotriene receptor antagonist class.

Cysteinyl leukotrienes are inflammatory chemicals produced during allergic responses. They can contribute to inflammation, nasal congestion, mucus production, and changes within the airways.

Montelukast blocks CysLT1 receptors and reduces the effects of these leukotrienes.

Each Bilafav M ODT Tablet contains montelukast sodium equivalent to montelukast 4 mg. The 4 mg strength is used in paediatric montelukast formulations, although the appropriate formulation and age range depend on the particular product and medical indication.

Do not add another montelukast 4 mg tablet or other montelukast-containing medicine unless it has specifically been prescribed. Bilafav M ODT already provides montelukast as part of the combination.

 

Bilafav M ODT 10/4 Composition

Bilafav M ODT contains:

Bilastine 10 mg + Montelukast Sodium equivalent to Montelukast 4 mg.

The ODT designation means the product is an orodispersible tablet, a dosage form intended to disintegrate rapidly rather than functioning like a conventional swallowed tablet.

Bilastine 10 mg is also available internationally as an orodispersible paediatric formulation. This type of dosage form can be useful where swallowing conventional tablets is difficult.

Because administration details can vary between individual ODT products, follow the directions printed on the Bilafav M ODT pack and the instructions provided by the prescriber or pharmacist. Do not automatically apply directions intended for a conventional bilastine tablet or a different brand of orodispersible medicine.

 

How to Use Bilafav M ODT

Use Bilafav M ODT exactly as prescribed.

Do not determine the montelukast dosage or bilastine dose from age alone. Body weight, indication, formulation, and individual medical factors may influence whether this combination is suitable.

As an orodispersible dosage form, Bilafav M ODT is designed for oral administration. Follow the product-specific instructions for allowing the tablet to disperse and taking it correctly.

Bilastine also has an important interaction with food. Standard bilastine treatment is generally taken:

  • at least one hour before food or fruit juice; or
  • at least two hours after food or fruit juice.

Food can reduce bilastine absorption, and fruit juices may also interfere with its absorption.

Do not increase the number of tablets because allergy symptoms continue. Persistent symptoms should be reviewed by the prescribing clinician.

If a dose is missed, follow the instructions given by the doctor or pharmacist. Do not automatically take two doses together to compensate.

 

Why Food and Fruit Juice Matter

Bilastine absorption is reduced when it is taken with food.

Fruit juices such as grapefruit juice can also reduce bilastine exposure by interfering with intestinal transport proteins involved in absorption. Similar effects may occur with other fruit juices.

This is why correct timing around meals is important for medicines containing bilastine.

Water is generally preferred when water is required with a bilastine-containing product. However, because Bilafav M ODT is an orodispersible formulation, use it according to its own pack instructions rather than assuming administration is identical to a conventional tablet.

A pharmacist at Grant Pharmacy can also help confirm the prescribed strength and explain the correct product-specific administration method before dispensing.

 

Paediatric Use and the 10/4 Strength

The 10 mg bilastine plus 4 mg montelukast combination uses strengths commonly associated with paediatric formulations.

Bilastine 10 mg orodispersible tablets are recognized in regulated product information for children within specified age and weight ranges. Clinical pharmacokinetic studies found that bilastine 10 mg in children can produce systemic exposure similar to bilastine 20 mg in adults.

Montelukast 4 mg is also an established paediatric strength. FDA-approved montelukast labeling includes 4 mg formulations for younger children in specific indications and age groups.

These facts do not mean that every child should receive Bilafav M ODT. The combination medicine should be prescribed only when both active ingredients are considered suitable.

Parents and caregivers should not substitute a bilastine 20 mg tablet, split adult-strength products, or add another montelukast preparation to recreate or modify the prescribed dose.

 

Important Precautions

Do not use Bilafav M ODT if the patient has a known allergy to bilastine, montelukast, or another ingredient in the formulation.

Tell the prescriber about kidney or liver problems and all other medicines being used.

Bilastine requires additional consideration when moderate or severe kidney impairment is present together with medicines that can increase bilastine concentrations.

Montelukast has an important safety warning concerning neuropsychiatric effects, which can involve changes in mood, behaviour, or sleep. The U.S. FDA requires a boxed warning for montelukast and recommends restricting its use for allergic rhinitis when other treatment options are effective and tolerated.

Parents and caregivers should be aware of meaningful behavioural, mood, or sleep changes during treatment and contact the prescriber promptly if these occur.

Do not use Bilafav M ODT as a substitute for medicine intended to relieve a sudden asthma attack. Montelukast is not a rescue treatment for acute bronchospasm.

 

Medicine Interactions

Bilastine can interact with medicines that influence transport proteins responsible for its movement through the body.

Relevant medicines can include:

  • ketoconazole
  • erythromycin
  • cyclosporine
  • ritonavir and
  • diltiazem.

These interactions may become more clinically important in people with impaired kidney function because bilastine exposure can increase.

Rifampicin may also influence pathways involved in bilastine transport.

Food and fruit juice are practical interaction considerations because they can reduce bilastine absorption.

Montelukast can also interact with certain medicines. Provide the prescriber with a complete list of prescription medicines, non-prescription treatments, vitamins, supplements, and herbal products before starting Bilafav M ODT. 

Do not discontinue another prescribed treatment solely because a potential interaction is identified. A healthcare professional should assess whether the combination is clinically important.

 

Common Side Effects

Bilafav M ODT may cause side effects, although not every patient experiences them.

With paediatric bilastine 10 mg treatment, reported common effects have included headache, abdominal discomfort, rhinitis, and allergic conjunctivitis. These effects were reported at rates broadly similar to placebo in clinical trials.

Montelukast can also be associated with effects such as headache, abdominal discomfort, upper respiratory symptoms, or other mild gastrointestinal complaints.

Common side effects are often manageable. Speak with the prescriber or pharmacist if they persist or become bothersome.

Bilastine generally has a low tendency to cause sedation, but individual responses differ. Any unexpected tiredness or dizziness should be discussed if it interferes with normal activity.

Do not reduce or increase the prescribed dose without consulting the healthcare professional managing treatment.

 

Bilastine in the USA

People searching for bilastine USA should understand that bilastine should not be assumed to be an FDA-approved medicine simply because the substance appears in regulatory databases.

The U.S. FDA maintains an identity record for bilastine, but substance registration does not mean that a finished bilastine medicine has FDA marketing approval.

Montelukast, by contrast, is FDA-approved for specific respiratory and allergic indications and is available in several strengths and dosage forms, including paediatric 4 mg formulations.

Bilafav M ODT as the specific Bilastine 10 mg and Montelukast 4 mg combination should not be described as an FDA-approved U.S. product.

Patients in the United States should use medicines approved and prescribed within their local healthcare system.

 

Bilafav M ODT and Bilafav M Are Different Strengths

Bilafav M ODT 10/4 should not be confused with Bilafav M 20/10.

The ODT product discussed here contains:

Bilastine 10 mg + Montelukast 4 mg.

The higher-strength Bilafav M formulation contains Bilastine 20 mg + Montelukast 10 mg.

These formulations should not be substituted for one another. The different ingredient strengths can correspond to different patient populations and treatment requirements.

Always check the full product name, dosage form, and both ingredient strengths before administration.

 

Practical Treatment Guidance

Use Bilafav M ODT at the prescribed time and maintain the recommended separation from food and fruit juice when instructed.

Avoid giving another antihistamine or montelukast-containing medicine unless the healthcare professional has reviewed the combination.

Reducing exposure to known allergens may also support treatment. Measures depend on the trigger and may include controlling indoor dust, reducing pollen exposure, or limiting contact with other known allergens.

If symptoms continue despite correct use, seek clinical advice instead of increasing the dose.

Persistent nasal symptoms may sometimes have causes other than allergy, so reassessment may be needed when treatment is not providing expected control.

 

Frequently Asked Questions

What is Bilafav M ODT 10/4 used for?

Bilafav M ODT contains bilastine 10 mg and montelukast 4 mg and is used for clinician-directed management of allergic conditions such as allergic rhinitis when combination treatment is considered appropriate.

What does Bilafav M ODT contain?

Each Bilafav M ODT Tablet contains Bilastine 10 mg and Montelukast 4 mg.

What does ODT mean?

ODT means orodispersible tablet. This dosage form is designed to disintegrate rapidly in the mouth. Follow the specific Bilafav M ODT pack instructions for administration.

Is Bilafav M ODT the same as Bilafav M 20/10?

No. Bilafav M ODT contains bilastine 10 mg plus montelukast 4 mg, while the higher-strength formulation contains bilastine 20 mg plus montelukast 10 mg. Do not interchange them without medical guidance.

Can Bilafav M ODT be taken with food?

Bilastine absorption is reduced by food. Bilastine treatment is generally separated from food and fruit juice by at least one hour before or two hours after intake. Follow the specific prescription instructions for this ODT formulation.

Can another montelukast 4 mg tablet be given with Bilafav M ODT?

Bilafav M ODT already contains montelukast 4 mg. Do not add another montelukast-containing medicine unless the prescriber specifically instructs you to do so.

Is Bilafav M ODT FDA-approved in the USA?

Bilastine has an FDA substance identity record, but that does not mean Bilafav M ODT is an FDA-approved U.S. product. Montelukast is separately FDA-approved for specific indications and carries an important boxed warning.

 

Responsible Ordering of Bilafav M ODT

Bilafav M ODT should be used only when the Bilastine 10 mg and Montelukast 4 mg combination and orodispersible dosage form are appropriate for the patient.

Confirm the exact medicine, both ingredient strengths, age and weight suitability, administration instructions, medical history, and current medicines before use.

Where delivery is permitted, Grant Pharmacy can arrange delivery to your doorstep, subject to prescription verification, applicable pharmacy rules, destination, and current availability.

 

Medically reviewed by the Grant Pharmacy Pharmacists Medical Team.

 

Medical References

Cipla – BILAFAV M Product Information

https://www.ciplamed.com/product-index/bilafav-m-tablets

Bilastine 20 mg Tablets – Paediatric Bilastine 10 mg Orodispersible Information

https://www.medicines.org.uk/emc/product/101237/smpc

Ilaxten – Bilastine 10 mg Orodispersible Tablet Patient Information

https://www.medicines.org.uk/emc/product/11727/pil

U.S. FDA – Montelukast Prescribing Information

https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020829s059lbl.pdf

U.S. FDA – Montelukast Boxed Warning and Allergic Rhinitis Guidance

https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug

Medical Disclaimer: The information provided on this page is for general informational purposes only and should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before using any medication or making healthcare-related decisions. Any reliance on the information provided is solely at your own risk. If you have any questions or concerns regarding the content on this website, please contact our administration team for assistance.

Author Details

Last updated 13 Nov 2026 | 06:05 AM (IST)

Reviews (0)

User Reviews

0.0
(0 Reviews)
5 stars
0
4 stars
0
3 stars
0
2 stars
0
1 stars
0

No reviews

Lowest Price Medicine
Price Match Guarantee
Medications as Promised

Newsletter